WALTHAM,
Mass., June 5, 2024 /PRNewswire/ -- Syndax
Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical
company developing an innovative pipeline of cancer therapies,
today announced that Michael A.
Metzger, Chief Executive Officer, will participate in a
fireside chat at the Goldman Sachs 45th Annual Global Healthcare
Conference on Wednesday, June 12,
2024, at 8:40 a.m. ET.
A live webcast of the fireside chat can be accessed from the
Investor section of the Company's website at www.syndax.com, where
a replay of the event will also be available for a limited
time.
About Syndax
Syndax Pharmaceuticals is a clinical stage biopharmaceutical
company developing an innovative pipeline of cancer therapies.
Highlights of the Company's pipeline include revumenib, a highly
selective menin inhibitor, and axatilimab, a monoclonal antibody
that blocks the CSF-1 receptor. For more information, please visit
www.syndax.com or follow the Company on X (formerly
Twitter) and LinkedIn.
Syndax Contact
Sharon
Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original
content:https://www.prnewswire.com/news-releases/syndax-announces-participation-at-the-goldman-sachs-45th-annual-global-healthcare-conference-302163121.html
SOURCE Syndax Pharmaceuticals, Inc.